Home
|
Site Map
|
Add to Favorites Link
|
Send page to a Friend
|
Contact us
About Us
Products
Research and Development
Publications and Press
Clinical Trials
Latest News
Contact us
Profile
Our mission
Partnerships
NGO and support groups
Contact Us
Medicines
Product licencing policy
Collaborate with us
Current projects
Future projects
A new model for pharmaceuticals
Scientific papers
In the news
Press release
Clinical reports
Projects
A NEW MODEL FOR PHARMACEUTICALS
Publicações científicas e monografias
P-MAPA-PRODUCT MONOGRAPH
Preview : This Monograph describes the state of art of the immunomodulator P-MAPA, that has been scientifically studied since the 80s by Brazilian, Chilean, European and American scientists.Its chemical and physical characteristics, biological properties, pre-clinical results and clinical trials results will be detailed and discussed, in order to explore its potential uses as a therapeutic
2nd World Conference - Ehrlich II - Nürnberg - 2008 -Structure and Antimalarial Activity of Immunomodulator P-MAPA
Preview : The P-MAPA activity against malaria ( Plasmodium chabaudi) was evaluated in groups of 7-10 C57BL/6 female mice, 5-8 week-old and pathogen-free.
Nanonization on biotechnological product: Nanocrystals and its polymorphisms-7 th Brazilian MRS Meeting 2008
Preview : The aim of present work was to compare two different nanonization processes starting from crystals of P-MAPA with size around 200μm
Immunopharmacology and Immunotoxicology - Volume 25, Number 3 / 2003
Preview :The present study examined the effects of P-MAPA, an antitumor aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride, isolated from Aspergillus oryzae, on concanavalin A-induced spleen cell proliferation, cytokine production and on NK cell activity in Ehrlich ascites tumor-bearing mice.
Nitric Oxide 14 - 2006 Macrophage nitric oxide -NO- stimulation by an immunomodulator: P-MAPA
Preview : this study asseded the ability of P-MAPA to modulate NO production by macrophages purified from peritoneal cavity of thioglycolate-treated mice
Antiviral Research-Volume 83, Issue 2, August 2009
Punta Toro virus, has been adapted to induce a Rift Valley fever virus-like disease in C57BL/6 mice. This virus has been used as a model to study the potential role of immunomodulating substances in therapies. Here, we report findings on the use of P-MAPA as an antiviral agent in a mouse model of acute phleboviral (Punta Toro virus) disease
Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Dis./Cancer
Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer: Compounds that can act as agonists for toll-like receptors (TLRs) may be promising candidates for the development of drugs against infectious diseases and cancer. The present study aimed to characterize the immunomodulatory effects of P-MAPA on TLRs in vitro and in vivo, as well as to investigate its potential as adjuvant therapy in infectious diseases and cancer
Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA
Acta tropica: This study investigated the immunotherapeutic potential of the protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immuno-modulator (P-MAPA) on canine visceral leishmaniasis.
International Immunopharmacology
International Immunopharmacology : Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis
[
First
] [
Previous
] [
1
] [
2
] [
3
] [
4
] [
5
] [
6
] [
7
] [
8
] [
9
] [
Next
] [
Last
]
Privacy Policy
|
Legal
|
copyright@2.006-farmabrasilis- all rights reserved